324 related articles for article (PubMed ID: 26273395)
1. Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements.
Wu S; Wang J; Zhou L; Su D; Liu Y; Liang X; Zhang S; Zeng X
Thorac Cancer; 2015 Jul; 6(4):413-20. PubMed ID: 26273395
[TBL] [Abstract][Full Text] [Related]
2. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
[TBL] [Abstract][Full Text] [Related]
5. ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases.
Song Z; Zheng Y; Wang X; Su H; Zhang Y; Song Y
J Thorac Dis; 2017 Oct; 9(10):3919-3926. PubMed ID: 29268402
[TBL] [Abstract][Full Text] [Related]
6. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
7. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
8. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma.
Zhu J; Cai L; Yang H; Wen Y; Wang J; Rong T; Shao J; Zhang L
Thorac Cancer; 2014 Sep; 5(5):411-6. PubMed ID: 26767032
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.
Xu Y; Chang H; Wu L; Zhang X; Zhang L; Zhang J; Li Y; Shen L; Zhu X; Zhou X; Bai Q
Exp Mol Pathol; 2020 Dec; 117():104548. PubMed ID: 32979347
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A; Grosse C; Rechsteiner M; Soltermann A
Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
[TBL] [Abstract][Full Text] [Related]
11. Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification.
Dong YJ; Cai YR; Zhou LJ; Su D; Mu J; Chen XJ; Zhang LI
Oncol Lett; 2016 Apr; 11(4):2552-2558. PubMed ID: 27073516
[TBL] [Abstract][Full Text] [Related]
12. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
13. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
14. Concordance of Immunohistochemistry and Fluorescence In Situ Hybridization in the Detection of Anaplastic Lymphoma Kinase (ALK) and Ros Proto-oncogene 1 (ROS1) Gene Rearrangements in Non-Small Cell Lung Carcinoma: A 4.5-Year Experience Highlighting Challenges and Pitfalls.
Nambirajan A; Sood R; Khatoon W; Malik PS; Mohan A; Jain D
Arch Pathol Lab Med; 2023 Dec; ():. PubMed ID: 38054562
[TBL] [Abstract][Full Text] [Related]
15. Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquid-based cytology.
Tanaka R; Sakamoto N; Suzuki H; Tachibana K; Ohtsuka K; Kishimoto K; Fujiwara M; Kamma H; Shibahara J; Kondo H
Diagn Cytopathol; 2019 Jun; 47(6):564-570. PubMed ID: 30741488
[TBL] [Abstract][Full Text] [Related]
16. EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.
Ju L; Han M; Zhao C; Li X
Lung Cancer; 2016 May; 95():94-7. PubMed ID: 27040858
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological characteristics of
Dugay F; Llamas-Gutierrez F; Gournay M; Medane S; Mazet F; Chiforeanu DC; Becker E; Lamy R; Léna H; Rioux-Leclercq N; Belaud-Rotureau MA; Cabillic F
Oncotarget; 2017 Aug; 8(32):53336-53351. PubMed ID: 28881815
[TBL] [Abstract][Full Text] [Related]
18. Quantitative volumetric assessment of the solid portion percentage on CT images to predict ROS1/ALK rearrangements in lung adenocarcinomas.
Zheng J; Zhou J; Liu J; Xu J; Sun K; Wang B; Cao H; Ding W; Zhou J
Oncol Lett; 2020 Sep; 20(3):2987-2996. PubMed ID: 32782616
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
Go H; Kim DW; Kim D; Keam B; Kim TM; Lee SH; Heo DS; Bang YJ; Chung DH
J Thorac Oncol; 2013 Nov; 8(11):1445-50. PubMed ID: 24128715
[TBL] [Abstract][Full Text] [Related]
20. Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.
Zhao M; Zhan C; Li M; Yang X; Yang X; Zhang Y; Lin M; Xia Y; Feng M; Wang Q
J Thorac Dis; 2018 Jan; 10(1):398-407. PubMed ID: 29600072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
